QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, June 17, 2009, 29(24):7633-7638; doi:10.1523/JNEUROSCI.0950-09.2009

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in J. Neurosci. Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Google Scholar Articles by Williams, J. H. Articles by Lutz, G. J. PubMed PubMed Citation Articles by Williams, J. H. Articles by Lutz, G. J.

 Previous Article  |  Next Article 

Brief Communications
Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy

Jason H. Williams, Rebecca C. Schray, Carlyn A. Patterson, Semira O. Ayitey, Melanie K. Tallent, and Gordon J. Lutz

Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102

Correspondence should be addressed to Gordon J. Lutz, Department of Pharmacology and Physiology, Drexel University College of Medicine, MS 488, NCB 8302, Philadelphia, PA 19102. Email: glutz{at}drexelmed.edu

Spinal muscular atrophy (SMA) is caused by homozygous mutation or deletion of the SMN1 gene encoding survival of motor neuron (SMN) protein, resulting in the selective loss of -motor neurons. Humans typically have one or more copies of the SMN2 gene, the coding region of which is nearly identical to SMN1, except that a point mutation causes splicing out of exon 7 and production of a largely nonfunctional SMN7 protein. The development of drugs that mitigate aberrant SMN2 splicing is an attractive therapeutic approach for SMA. A steric block antisense oligonucleotide (AO) has recently been developed that blocked an intronic splice suppressor element, and enhanced SMN2 exon 7 inclusion in SMA patient fibroblasts. Here, we show that periodic intracerebroventricular (ICV) delivery of this AO resulted in increased SMN expression in brain and spinal cord to as much as 50% of the level of healthy littermates. Real-time PCR of SMN2 transcripts confirmed the AO-mediated increase in full-length SMN. The AO-derived increase in SMN expression led to a concomitant improvement in bodyweight throughout the lifespan of the SMA animals. Treatment of SMA mice with AO also provided partial correction of motor deficits, manifest as improved righting response. Injections of a scrambled oligonucleotide had no effect on SMN expression or phenotype in the SMA mice. Our results validate that AOs that abrogate aberrant splicing of SMN2 are promising compounds for treating SMA.

---

Received Feb. 23, 2009; revised May 3, 2009; accepted May 4, 2009.

Correspondence should be addressed to Gordon J. Lutz, Department of Pharmacology and Physiology, Drexel University College of Medicine, MS 488, NCB 8302, Philadelphia, PA 19102. Email: glutz{at}drexelmed.edu

Related articles in J. Neurosci.:

This Week in The Journal

J. Neurosci. 2009 29: i. [Full Text]  

This article has been cited by other articles:

				A. B. Young Four Decades of Neurodegenerative Disease Research: How Far We Have Come! J. Neurosci., October 14, 2009; 29(41): 12722 - 12728. [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help